A newly identified inflammatory ‘workaround’ could explain why blockbuster arthritis drugs fail some patients.
For people living with rheumatoid arthritis (RA), modern medicine has offered something close to relief. Over the past 25 years, TNF inhibitors, biologic drugs designed to block a major inflammatory signal, have helped millions manage pain, swelling and joint damage. These drugs became a cornerstone of autoimmune care and a multibillion-dollar market.
And yet, for a significant minority of patients, the promise falls short. Up to 40% see little benefit, while others respond at first only to watch the effects fade. For years, researchers have asked a simple but unsettling question: why does inflammation keep going even when its main driver is blocked?
A new study led by Washington State University (WSU) researchers suggests the answer may be surprisingly mundane. Inflammation, it turns out, may be slipping in through a back door [1].
Published in Cellular & Molecular Immunology, the study identifies an alternate inflammatory pathway involving two lesser-known proteins: TWEAK and its receptor, Fn14. While TNF has long been viewed as the central villain in RA, TWEAK belongs to the same extended protein family and appears to quietly assist TNF when conditions allow.
Think of TNF as the main highway feeding inflammation into the joints. TNF inhibitors act like toll booths, slowing or stopping traffic. What the WSU team found is that TWEAK and Fn14 function more like an unguarded side road. Even when the highway is blocked, inflammatory signals can still get through.
“It’s kind of like a back-door entry or an alternate route,” said Salah-uddin Ahmed, professor and associate dean for research and graduate education at WSU’s College of Pharmacy and Pharmaceutical Sciences. “If you shut the main door for TNF, it has other ways to cause inflammation [2].”
How the ‘back door’ amplifies damage
The researchers examined human joint tissue alongside data from rat studies, focusing on how inflammatory signals interact inside synovial fibroblasts, the cells that line joints and play a key role in RA damage.
They found that when TWEAK activates its receptor Fn14, it works alongside TNF to amplify inflammation. When both signals are active, inflammatory activity surges. But when the Fn14 pathway is blocked, TNF’s ability to drive inflammation drops dramatically.
“What we found was when you block Fn14 or knock down Fn14, the power of TNF to cause inflammation was reduced significantly,” Ahmed said. “This was telling us TNF heavily relied on this receptor to cause inflammation [2].”
This molecular “crosstalk” between TNF and Fn14, described for the first time in this study, helps explain why blocking TNF alone doesn’t always work. The system is more collaborative and more resilient than previously thought.
TNF inhibitors are prescribed not just for RA, but for conditions such as Crohn’s disease, ulcerative colitis and ankylosing spondylitis. In 2024, the market for these drugs was estimated at around $25 billion.
“These are fantastic for the majority of patients,” Ahmed said. “But roughly 30% to 40% of patients don’t respond.”
From a clinical perspective, the findings offer a biological explanation that patients have long sensed intuitively: persistent inflammation isn’t always about the wrong drug; it may be about an incomplete strategy.
The implications are truly significant. As leading TNF inhibitors face biosimilar competition and slowing growth, new targets like Fn14 could represent the next phase of autoimmune drug development. Rather than replacing TNF inhibitors, future therapies may work alongside them, targeting multiple inflammatory pathways simultaneously.
Rheumatoid arthritis affects about 1% of the global population and often strikes during midlife, precisely when people expect to be at their most active and productive. Left poorly controlled, RA doesn’t just damage joints; it accelerates disability, raises cardiovascular risk and chips away at healthspan.
The study reinforces a broader idea gaining traction across aging research: chronic inflammation is rarely driven by a single switch. Instead, it’s sustained by networks that adapt when one pathway is blocked.
This has implications beyond RA. TNF plays a role in multiple autoimmune and inflammatory diseases, suggesting that Fn14 could be relevant far outside rheumatology. Targeting these “backup systems” may prove essential to slowing the long-term, body-wide wear and tear that undermines healthy aging.
What comes next
Ahmed and his team now plan to explore two therapeutic directions: one that targets both TNF and Fn14 together, and another that focuses specifically on the Fn14 pathway. Either approach could help explain and eventually overcome drug resistance that has frustrated patients and clinicians alike.
“This is almost like a partner in crime for TNF,” Ahmed said.
The study that shows how “TWEAK receptor (Fn14) exacerbates TNF-α-induced inflammation in rheumatoid arthritis synovial fibroblasts and influences response to anti-TNF-α therapy” doesn’t offer an overnight solution. But it reframes a long-standing problem in autoimmune medicine and points toward a more nuanced future.
In the biology of aging and disease, shutting the front door is rarely enough. The real challenge is finding and closing the routes we didn’t know were there.
[1] https://www.nature.com/articles/s41423-026-01386-y
[2] https://news.wsu.edu/press-release/2026/01/30/study-identifies-alternate-path-for-inflammation-that-could-improve-ra-treatment/
